Martina Imbimbo

9PUBLICATIONS
113CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cellular immunologyMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 17, 2026
Combinatorial Delivery of Low-Dose Radiotherapy and Immunotherapy to Patients with Immune-Excluded Tumors Enhances CD8+ T-cell Functionality.

|Jan 10, 2026
ChronoimmunoTOX: A Single-Institution Retrospective Study on How the Time of Administration Impacts Immune Checkpoint Inhibitor Efficacy and Toxicity in Melanoma.

Alessandro Nepote, Gilles Burghgraeve, Martino Pedrani

|Dec 30, 2025
A Real-World Experience on the Efficacy of First-Line Treatment with Immune-Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%: The Role of KRAS Mutations.

Lucia Motta, Samantha Epistolio, Jana Pankovics

|Sep 03, 2025
IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors.

John Powderly, Martina Imbimbo, Antoine Italiano

|Feb 02, 2024
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma.

David Barras, Eleonora Ghisoni, Johanna Chiffelle

|Nov 08, 2023
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.

Yvette Drew, Jae-Weon Kim, Richard T Penson

Pageof 2

Frequent Collaborators

3 joint publications

Denarda Dangaj Laniti

3 joint publications

Maria Ochoa-de-Olza

3 joint publications

Fabrizio Benedetti

3 joint publications

Clarisse Dromain